Overview

Update
Primary Role
Board of Directors @
Investments
9 Investments in 5 Companies
Gender:
Male
Location:
Austin
Social:

Person Details

Update
Aliases:
Lou Bock

Lou focuses on identifying emerging biopharmaceutical, device and platform technology companies. He sits on the Boards of Ascenta Therapeutics, Century Hospice, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVP’s investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).

Lou joined ScaleVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead’s approved antiviral drug, Vistide, and was responsible for the discovery of Gilead’s novel thrombin aptamer. Prior to Gilead, he was a research associate at Genentech.

Jobs (9)

Update
Current

Director

Venture Partner

Director

Aug, 2006 - Current   (about 10 years)
Past
Started
Ended
Title
Company
Unknown
Unknown
Research Scientist, Project Manager, Business Development & Sales
Jan 1, 2007
Jun 30, 2014
Partner
Nov, 1987
Sep, 1989
Research Associate

Board & Advisor Roles (8)

Update

Education (1)

Update

Add News

Add Memberships

Add Images

Add Videos